

DRAFT

**Ohio Department of Job and Family Services (ODJFS)
Drug Utilization Review (DUR) Board
Quarterly Meeting
February 26, 2013**

The quarterly meeting of the ODJFS DUR Board was called to order at 12:00 PM in Room 1932, 19th Floor Riffe Center, 77 S. High St. Columbus, Ohio. David Brookover, RPh, presided. The following Board members were present:

David Brookover, RPh, Chair
Thomas Gretter, MD
Robert Kubasak, RPh
Kevin Mitchell, RPh
J. Layne Moore, MD
Lenard Presutti, DO
Donald Sullivan, RPh, PhD

Also present were Margaret Scott, RPh, DUR Administrator; Mike Howcroft, RPh, Medicaid pharmacist, Jill Griffith, RPh, DUR Director; and Pam Heaton RPh, PhD from the University Of Cincinnati College Of Pharmacy. Approximately 11 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The November 13th, 2012, DUR Board minutes were approved. (1st T. Gretter, 2nd K. Mitchell).

New Business:

M. Scott reviewed the DUR Board Conflict of Interest Policy. The Board approved quantity per day limits for drugs in the Analgesic, Blood, Cardiovascular, CNS and Endocrine Agents therapeutic categories (1st R. Kubasak, 2nd L. Presutti). Prior Authorization (PA) will be required to exceed the approved quantity limits.

Health Plan Policy:

M. Scott gave the Health Plan Policy report: Medicaid is not expected to be affected by sequestration. The budget proposal to expand Medicaid coverage to citizens up to 138-percent of the Federal Poverty Level is working through the Ohio legislative approval process. The ODJFS Office of Ohio Health Plans has been re-named the Office of Medical Assistance (OMA). OMA is autonomous within ODJFS. OMA becomes the Department of Medicaid and will be a separate cabinet-level agency by July 1, 2013.

DRAFT

DUR Committee Report:

J. Griffith announced that the December DUR Committee reviewed 3,522 profiles of patients with claims for four or more albuterol inhalers in a three-month time period. The January DUR Committee reviewed 767 profiles of patients receiving combination inhalers concurrently which duplicate single ingredient inhalers or are receiving more than one inhaler from the same therapeutic category. The February DUR Committee edited and reviewed letters. The Board reviewed, discussed, edited and approved the letter sets for the December and January Committee reviews. The Board also approved a letter set to be used in partnership with the Best Evidence for Advancing Childhealth in Ohio Now (BEACON) group.

Unfinished Business:

P. Heaton presented the final results of study to identify the frequency of long-acting benzodiazepine use among Medicaid elderly with waiver programs and determine if there is an association between long-acting benzodiazepine use and health outcomes. The study showed 4.4 percent of patients above age 65 received long-acting benzodiazepines. A regression analysis showed no association between long-acting benzodiazepine use and health outcomes.

M. Howcroft presented an update on psychotropic use in youth and nursing facility patients. A medication reference table has been proposed for inclusion in the *Minds Matter* project educational toolkit. The Board provided suggestions to help make the table understandable to parents and patients. The State is working to decrease psychiatric drug use in the elderly population by 15 percent. A survey tool is under development to assess nursing home psychiatric drug use.

Announcements:

The second quarter 2013 DUR Board meeting is scheduled for noon on Tuesday, May 21st, location to be announced.

Adjournment:

David Brookover, RPh adjourned the meeting at 12:52 PM (1st T. Gretter, 2nd J. Moore).

Respectfully submitted:

Jill RK Griffith BS, PharmD, DUR Program Director